 CAMBRIDGE, England BOSTON--BUSINESS WIRE--Bicycle Therapeutics plc Nasdaq: BCYC, a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide Bicycle technology, today announced the pricing of an underwritten public offering of 3,240,741 American Depositary Shares ADSs, each representing one ordinary share, at a price to the public of 54.00 per ADS, for gross proceeds of 175.0 million. In addition, Bicycle has granted 